Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013735" target="_blank" >RIV/00023736:_____/24:00013735 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10489271 RIV/65269705:_____/24:00081409
Result on the web
<a href="https://doi.org/10.1200/JCO.24.00490" target="_blank" >https://doi.org/10.1200/JCO.24.00490</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.24.00490" target="_blank" >10.1200/JCO.24.00490</a>

Result language
angličtina
Original language name
Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
Original language description
The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. PATIENTS AND METHODSE WALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870). Patients age 55 years and older with newly diagnosed CD22+ Philadelphia chromosome-negative (Ph-) B-cell precursor (BCP) ALL were eligible. Our results support InO's use in first-line regimens for older patients with CD22+ Ph- BCP-ALL.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)